Finanzen von Theriva Biologics Inc (TOVX)TOVXTheriva Biologics Inc

Evaluating the bottom line, Theriva Biologics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1807.33%, while the net margin is -1753.67%. These profitability ratios, combined with a Return on Equity (ROE) of -115.11%, provide a clear picture of how effectively TOVX converts its operational activities into shareholder value.

In the context of the broader market, TOVX competes directly with industry leaders such as TPST and APRE. With a market capitalization of $7.56M, it holds a significant position in the sector. When comparing efficiency, TOVX's gross margin of 100.00% stands against TPST's N/A and APRE's N/A. Such benchmarking helps identify whether Theriva Biologics Inc is trading at a premium or discount relative to its financial performance.

Theriva Biologics reported a net loss of $2.04 million for Q1 2026, which is an improvement from previous losses, indicating some operational efficiency. However, total revenue remains very low, with $300,000 reported for Q1 2026, and no revenue in the preceding quarters.